Azienda Socio Sanitaria Territoriale Ovest Milanese — Clinical Trial Site

28 Registered trials

15 Currently recruiting

Organisation

Azienda Socio Sanitaria Territoriale Ovest Milanese

Location

Legnano, Italy

Identifier

ORG-100045241

Address

Via Papa Giovanni Paolo II, 20025, Italy

Departments

380019: Ematologia
Anesthesia and Intensive Care
chirurgia generale
Gastroenterology
Gastroenterology (Civil Hospital of Legnano)
Gastroenterology Department
Hematology
Medical oncology
Nefrologia e Dialisi
Oncologia
Oncology
Ospedale di Legnano
S.C. Ematologia
S.C. Oncologia medica
SS Anaestesiologist
U.O. Oncologia Medica
U.O.C. Ematologia
UOC NEUROLOGIA - STROKE UNIT
UOC Oncologia

Clinical trials at this site (28)

Search interface

MELFLUFEN FOR ELDERLY PATIENTS WITH RELAPSED MYELOMA Not authorised

2024-514652-33-00 Relapsed Multiple Myeloma 4
A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatm… Pending

2024-519087-41-00 Breast cancer is the most common form of cancer among w 5
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending

2025-521037-86-00 Immune system diseases 5
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti… Pending

2025-521038-27-00 Immune system diseases 5
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting

2024-516906-47-00 Locally Advanced or Metastatic Urothelial Carcinoma 10 2025-11-28
Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting

2025-521775-31-00 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutatio 5 2025-11-12
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting

2025-521036-11-00 Immune system disseases 5 2026-03-23
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting

2025-521035-37-00 Immune system diseases 5 2026-03-02
PROBHE: Prehabilitation with Botulinum Toxin A in complex hernia: an Italian prospective study on predictive scores of myofascial release. Recruiting

2025-522451-25-00 Large hernia width, chronically retracted lateral abdom 4 2026-02-17
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Recruiting

2025-521242-26-00 Moderately to Severely Active Ulcerative Colitis 4 2025-11-27
A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab… Recruiting

2024-519827-16-00 Newly Diagnosed Transplant Ineligible Multiple Myeloma 5 2025-09-30
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer Recruiting

2024-515884-69-00 Extensive Stage Small Cell Lung Cancer (ES-SCLC) 5 2025-07-16
The use of Landiolol in mitral valve sUrgery: a raNdomized, controlled, double-blind triAl. (LUNA) Recruiting

2024-515934-34-00 Low-cardiac output syndrome (LCOS) 6 2025-01-28
Efecto de la inmunoterapia en pacientes con cáncer de pulmón de células no pequeñas oligometastásico (número limitado de metástasis) después… Recruiting

2023-508741-40-00 Non-small cell lung cancer 10 2025-01-14
Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI… Recruiting

2024-517863-22-00 Study population consists in patients with a diagnosis 5 2024-12-01
Prospective comparative randomized study of procedural sedation during TAVR (Transcatheter Aortic Valve Replacement) Recruiting

2024-511018-18-00 patients with aortic stenosis underwent transcatheter a 5 2024-08-09
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left … Recruiting

2023-509551-14-00 Unresectable left sided RAS/B-RAF wild-type metastatic 5 2024-06-12
C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL… Recruiting

2023-507871-23-00 Relapsed/Refractory Multiple Myeloma 5 2024-05-27
Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3) Recruiting

2022-500587-35-01 Stroke 5 2023-07-06
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monot… Ended

2023-506668-15-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2024-06-17
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-… Ended

2022-502446-27-00 Relapsed or Refractory Myeloma 5 2024-02-26
Clinical trial to compare selinexor pomalidomide dexamethasone combination with elotuzumab pomalidomide dexamethasone in multiple myeloma pa… Ended

2024-518304-53-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2022-02-02
Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph… Ended

2024-511636-27-00 Follicular Lymphoma 5 2021-12-01